Triathlon Knee Replacement for Knee Arthritis
(APT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to assess the effectiveness of the Triathlon All-Polyethylene Tibia Knee device in individuals with knee arthritis. Researchers seek to understand the device's impact on knee function and overall mobility. It is intended for those who have already undergone this specific knee replacement and do not have infections or significant knee instability. Participants must commit to regular follow-ups and check-ups after surgery. As an unphased trial, this study provides participants the opportunity to contribute to valuable research that could enhance future knee replacement outcomes.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that the Triathlon All-Polyethylene Tibia Knee device is safe?
Research shows that patients generally receive the Triathlon All-Polyethylene Tibia Knee device well. Studies have demonstrated positive results with this knee replacement. Notably, one study found that it moves less after implantation compared to metal-backed parts. This reduces the chance of the knee becoming loose over time, promising long-term stability.
The available research has not reported any specific serious side effects linked to this device. While all medical procedures carry some risks, current evidence suggests that the Triathlon All-Polyethylene Tibia Knee is a safe choice for those needing knee replacement.12345Why are researchers excited about this trial?
The Triathlon All-Polyethylene Tibia Knee is unique because it uses a single polyethylene material for the tibial component in knee replacements, which differs from the typical metal and polyethylene combination. This design aims to reduce wear and tear, potentially increasing the longevity of the knee replacement. Researchers are excited about this treatment as it could offer a more durable solution for those suffering from knee arthritis, potentially reducing the need for revision surgeries and improving long-term outcomes for patients.
What evidence suggests that the Triathlon All-Polyethylene Tibia Knee device is effective for knee arthritis?
Studies have shown that the Triathlon All-Polyethylene Tibia Knee device, which all participants in this trial will receive, may benefit people with knee arthritis. Research suggests that using all-plastic parts in knee replacements might outperform those with metal backing. A review of several studies found that these plastic parts can lead to better results in knee replacement surgery. Specifically, patients with a higher body mass index (BMI) who received this device had good outcomes at least two years after surgery. This suggests the device might improve knee function and reduce pain.12678
Are You a Good Fit for This Trial?
This trial is for adults over 18 who have had a primary total knee replacement using the Triathlon All-Polyethylene Tibia and compatible components, without plans for revision. Participants must be able to follow up with clinical evaluations. Those with infections, compromised bone stock, mental or neuromuscular disorders, excessive steroid use, or are prisoners cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Retrospective Data Collection
Data obtained retrospectively from medical records from preoperative to shortly after surgery
Follow-up
Participants are evaluated at their 5-year and 10-year post-surgery anniversary dates
What Are the Treatments Tested in This Trial?
Interventions
- Triathlon All-Polyethylene Tibia Knee
Triathlon All-Polyethylene Tibia Knee is already approved in United States, European Union for the following indications:
- Painful, disabling joint disease of the knee resulting from non-inflammatory degenerative joint disease (including osteoarthritis, traumatic arthritis, or avascular necrosis)
- Rheumatoid arthritis or post-traumatic arthritis
- Post-traumatic loss of knee joint configuration and function
- Moderate varus, valgus, or flexion deformity in which the ligamentous structures can be returned to adequate function and stability
- Revision of previous unsuccessful knee replacement or other procedure
- Fracture of the distal femur and/or proximal tibia that cannot be stabilized by standard fracture management techniques
- Painful, disabling joint disease of the knee resulting from non-inflammatory degenerative joint disease (including osteoarthritis, traumatic arthritis, or avascular necrosis)
- Rheumatoid arthritis or post-traumatic arthritis
- Post-traumatic loss of knee joint configuration and function
- Moderate varus, valgus, or flexion deformity in which the ligamentous structures can be returned to adequate function and stability
- Revision of previous unsuccessful knee replacement or other procedure
- Fracture of the distal femur and/or proximal tibia that cannot be stabilized by standard fracture management techniques
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stryker Orthopaedics
Lead Sponsor
Kevin A. Lobo
Stryker Orthopaedics
Chief Executive Officer since 2012
Bachelor's degree in Commerce from McGill University, MBA from University of Toronto
Dr. Jorge Enrique Diaz
Stryker Orthopaedics
Chief Medical Officer since 2023
MD from University of Michigan Medical School